![](/images/graphics-bg.png)
Recombinant Human Thyroid Stimulating Hormone versus Thyroid Hormone Withdrawal for Radioactive Iodine Treatment of Differentiated Thyroid Cancer with Nodal Metastatic Disease
Joint Authors
Wolfson, Robert M.
Morrison, Deric
Driedger, Al
Spaic, Tamara
Van Uum, Stanislaus H. M.
Rachinsky, Irina
Source
Issue
Vol. 2016, Issue 2016 (31 Dec. 2016), pp.1-6, 6 p.
Publisher
Hindawi Publishing Corporation
Publication Date
2016-02-09
Country of Publication
Egypt
No. of Pages
6
Main Subjects
Abstract EN
Introduction.
Recombinant human thyroid stimulating hormone (rhTSH) is approved for preparation of thyroid remnant ablation with radioactive iodine (RAI) in low risk patients with well differentiated thyroid cancer (DTC).
We studied the safety and efficacy of rhTSH preparation for RAI treatment of thyroid cancer patients with nodal metastatic disease.
Methods.
A retrospective analysis was performed on 108 patients with histopathologically confirmed nodal metastatic DTC, treated with initial RAI between January 1, 2000, and December 31, 2007.
Within this selected group, 31 and 42 patients were prepared for initial and all subsequent RAI treatments by either thyroid hormone withdrawal (THW) or rhTSH protocols and were followed up for at least 3 years.
Results.
The response to initial treatment, classified as excellent, acceptable, or incomplete, was not different between the rhTSH group (57%, 21%, and 21%, resp.) and the THW group (39%, 13%, and 48%, resp.; P=0.052).
There was no significant difference in the final clinical outcome between the groups.
The rhTSH group received significantly fewer additional doses of RAI than the THW group (P=0.03).
Conclusion.
In patients with nodal-positive DTC, preparation for RAI with rhTSH is a safe and efficacious alternative to THW protocol.
American Psychological Association (APA)
Wolfson, Robert M.& Rachinsky, Irina& Morrison, Deric& Driedger, Al& Spaic, Tamara& Van Uum, Stanislaus H. M.. 2016. Recombinant Human Thyroid Stimulating Hormone versus Thyroid Hormone Withdrawal for Radioactive Iodine Treatment of Differentiated Thyroid Cancer with Nodal Metastatic Disease. Journal of Oncology،Vol. 2016, no. 2016, pp.1-6.
https://search.emarefa.net/detail/BIM-1109709
Modern Language Association (MLA)
Wolfson, Robert M.…[et al.]. Recombinant Human Thyroid Stimulating Hormone versus Thyroid Hormone Withdrawal for Radioactive Iodine Treatment of Differentiated Thyroid Cancer with Nodal Metastatic Disease. Journal of Oncology No. 2016 (2016), pp.1-6.
https://search.emarefa.net/detail/BIM-1109709
American Medical Association (AMA)
Wolfson, Robert M.& Rachinsky, Irina& Morrison, Deric& Driedger, Al& Spaic, Tamara& Van Uum, Stanislaus H. M.. Recombinant Human Thyroid Stimulating Hormone versus Thyroid Hormone Withdrawal for Radioactive Iodine Treatment of Differentiated Thyroid Cancer with Nodal Metastatic Disease. Journal of Oncology. 2016. Vol. 2016, no. 2016, pp.1-6.
https://search.emarefa.net/detail/BIM-1109709
Data Type
Journal Articles
Language
English
Notes
Includes bibliographical references
Record ID
BIM-1109709